Log in

NASDAQ:ICADiCAD Stock Price, Forecast & News

-0.08 (-0.76 %)
(As of 08/7/2020 04:00 PM ET)
Today's Range
Now: $10.40
50-Day Range
MA: $9.99
52-Week Range
Now: $10.40
Volume188,719 shs
Average Volume318,730 shs
Market Capitalization$237.82 million
P/E RatioN/A
Dividend YieldN/A
iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. It operates through two segments, Cancer Detection and Cancer Therapy. The company provides electronic brachytherapy (eBX) products, including Axxent eBx systems for the treatment of early stage breast cancer, endometrial cancer, cervical cancer, and skin cancer, as well as for treating other cancers or conditions where radiation therapy is indicated comprising intraoperative radiation therapy. It also offers digital mammography computer-aided detection (CAD) products, such as advanced image analysis and workflow solutions in breast imaging, which include PowerLook Mammo Detection, which detects and identifies suspicious masses and micro-calcifications; and PowerLook Advanced Mammography Platform, a computer server residing on a customer's network that receives patient studies from the imaging modality, performs CAD and density assessment analysis, and sends the CAD results to picture archiving and communication system and/or review workstations. In addition, the company's digital mammography CAD products comprise magnetic resonance imaging products to detect breast and prostate cancer; breast tomosynthesis systems; and advanced image analysis and workflow solutions in computed tomography (CT) colonography, including VeraLook that supports the detection of colonic polyps in conjunction with CT colonography. It serves hospitals, ambulatory care centers and free standing radiation oncology facilities, and other office-based uses through sales organizations, as well as through various original equipment manufacturer partners, distributors, and resellers. iCAD, Inc. has a strategic partnership agreement with Invivo Corp. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was founded in 1984 and is headquartered in Nashua, New Hampshire.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.33 out of 5 stars

Industry, Sector and Symbol

Industry Surgical & medical instruments
Current SymbolNASDAQ:ICAD



Sales & Book Value

Annual Sales$31.34 million
Book Value$0.26 per share


Net Income$-13,550,000.00


Market Cap$237.82 million
Next Earnings Date11/4/2020 (Estimated)
-0.08 (-0.76 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ICAD News and Ratings via Email

Sign-up to receive the latest news and ratings for ICAD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

iCAD (NASDAQ:ICAD) Frequently Asked Questions

How has iCAD's stock been impacted by COVID-19 (Coronavirus)?

iCAD's stock was trading at $11.12 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ICAD shares have decreased by 6.5% and is now trading at $10.40.
View which stocks have been most impacted by Coronavirus

Do Wall Street analysts recommend investors buy shares of iCAD?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for iCAD in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for iCAD

When is iCAD's next earnings date?

iCAD is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for iCAD

How were iCAD's earnings last quarter?

iCAD Inc (NASDAQ:ICAD) issued its quarterly earnings data on Tuesday, August, 4th. The technology company reported ($0.12) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.16) by $0.04. iCAD had a negative return on equity of 109.82% and a negative net margin of 69.88%.
View iCAD's earnings history

What price target have analysts set for ICAD?

4 Wall Street analysts have issued 12 month price objectives for iCAD's shares. Their forecasts range from $10.00 to $15.00. On average, they anticipate iCAD's stock price to reach $13.50 in the next twelve months. This suggests a possible upside of 29.8% from the stock's current price.
View analysts' price targets for iCAD

Has iCAD been receiving favorable news coverage?

Media coverage about ICAD stock has trended very positive recently, InfoTrie reports. The research firm ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. iCAD earned a news sentiment score of 4.0 on InfoTrie's scale. They also gave news stories about the technology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days.
View the latest news about iCAD

Who are some of iCAD's key competitors?

What other stocks do shareholders of iCAD own?

Based on aggregate information from My MarketBeat watchlists, some companies that other iCAD investors own include Inseego (INSG), Marvell Technology Group (MRVL), NVIDIA (NVDA), Crispr Therapeutics (CRSP), Fulgent Genetics (FLGT), Intellia Therapeutics (NTLA), InVitae (NVTA), Aptiv (APTV), Alibaba Group (BABA) and Niu Technologies (NIU).

Who are iCAD's key executives?

iCAD's management team includes the following people:
  • Ms. Stacey M. Stevens, Pres (Age 51)
  • Mr. Michael S. Klein, Exec. Chairman & CEO (Age 65)
  • Mr. R. Scott Areglado, VP, Corp. Controller & Interim CFO (Age 55)
  • Mr. Jonathan Go, Chief Technology Officer (Age 56)
  • Ms. Annette L. Heroux, VP of Admin. (Age 62)

What is iCAD's stock symbol?

iCAD trades on the NASDAQ under the ticker symbol "ICAD."

Who are iCAD's major shareholders?

iCAD's stock is owned by many different retail and institutional investors. Top institutional investors include Russell Investments Group Ltd. (1.41%), Calamos Advisors LLC (1.17%), Sturgeon Ventures LLP (0.39%), Cadence Capital Management LLC (0.34%), UBS Group AG (0.12%) and New York State Common Retirement Fund (0.08%). Company insiders that own iCAD stock include Andy Sassine and Stacey M Stevens.
View institutional ownership trends for iCAD

Which institutional investors are buying iCAD stock?

ICAD stock was purchased by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Calamos Advisors LLC, Sturgeon Ventures LLP, UBS Group AG, New York State Common Retirement Fund, Strs Ohio, SG Americas Securities LLC, and Cadence Capital Management LLC.
View insider buying and selling activity for iCAD

How do I buy shares of iCAD?

Shares of ICAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is iCAD's stock price today?

One share of ICAD stock can currently be purchased for approximately $10.40.

How big of a company is iCAD?

iCAD has a market capitalization of $237.82 million and generates $31.34 million in revenue each year. The technology company earns $-13,550,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. iCAD employs 95 workers across the globe.

What is iCAD's official website?

The official website for iCAD is www.icadmed.com.

How can I contact iCAD?

iCAD's mailing address is 98 SPIT BROOK ROAD SUITE 100, NASHUA NH, 03062. The technology company can be reached via phone at 603-882-5200 or via email at [email protected]

This page was last updated on 8/8/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.